Use of pharmaceutical composition for preventing and treating novel coronavirus pneumonia
Patent Information
- Application Number
- LAP845
- Authority / Receiving Office
- LA · LA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-03-02
- Filing Date
- 2021-02-02
- Publication Date
- 2026-02-27
AI Technical Summary
Existing antiviral drugs are ineffective against new coronavirus pneumonia and have toxicity issues, and there is a lack of safe and effective treatment options.
A pharmaceutical composition was developed, which is composed of volatile oils and alcohol extracted from traditional Chinese medicines such as patchouli, forsythia, ephedra, houttuynia cordata, rhubarb, honeysuckle, gypsum, isatis root, Mianma Guanzhong, licorice, and rhodiola. The liquid composition is made through a specific extraction and concentration process, and is combined with menthol to form active ingredients, which are used to prepare capsules, granules and other dosage forms for the prevention and treatment of pneumonia caused by new coronavirus infection.
The pharmaceutical composition has shown significant anti-novel coronavirus and anti-inflammatory activity in vitro and in clinical trials, can effectively inhibit virus replication and expression of inflammatory factors, significantly improve symptoms such as fever, cough, and fatigue, and is safe in clinical applications. Good, no obvious adverse reactions.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
Use of a pharmaceutical composition in the prevention and treatment of coronavirus disease 2019 (COVID-19) This application claims priority to the following Chinese patent applications: Chinese Patent Application No. 202010079857.2, filed with the Chinese Patent Office on February 4, 2020; Chinese Patent Application No. 202010094502.0, filed with the Chinese Patent Office on February 16, 2020; Chinese Patent Application No. 202010105903.1, filed with the Chinese Patent Office on February 21, 2020; and Chinese Patent Application No. 202010134508.6, filed with the Chinese Patent Office on March 2, 2020. The contents of all of them are incorporated herein by reference in their entirety. Technical Field The present invention relates to the use of a pharmaceutical composition in the preparation of a medicament for preventing and treating coronavirus disease 2019 (COVID-19), and belongs to the field of medicine. Background Art On January 12, 2020, the World Health Organization officially named the novel coronavirus as "2019 novel coronavirus (2019-nCoV)". The Lancet published research results from which they sequenced and analyzed the pathogen of 2019 novel coronavirus (2019-nCoV) from patient samples and found that it has significant genetic differences from the severe acute respiratory syndrome (SARS) virus that prevailed in 2003 and the Middle East respiratory syndrome (MERS) virus discovered in 2012. Systematic analysis shows that this virus belongs to the Sarbecovirus subtype of the genus Betacoronavirus and is genetically distant from the SARS virus. It is reported that this coronavirus belongs to an enveloped single-stranded positive-sense RNA virus, and the pathogen 2019-nCoV and its genomic sequence have been clarified, laying an important foundation for epidemic prevention work. Pneumonia caused by novel coronavirus infection, also known as coronavirus disease 2019 (COVID-19), is mainly manifested clinically as fever, fatigue, and dry cough, and a few cases are accompanied by symptoms such as nasal congestion, runny nose, sore throat, and diarrhea. Severe cases may show dyspnea and endanger life. This disease has a high infectivity. Some researchers used a model to evaluate the "basic reproductive number" (RO) of this epidemic to be 2.2. Currently available antiviral drugs such as Tamiflu (oseltamivir phosphate) have no good therapeutic effect on the novel coronavirus pneumonia virus. Because oseltamivir is a neuraminidase inhibitor that acts on the neuraminidase component on the cell membrane of influenza A and B viruses, and the novel coronavirus does not have neuraminidase, so Tamiflu will not have a therapeutic effect on the novel coronavirus. Clinical manifestations: The main manifestations are fever, fatigue, and dry cough. A small number of patients are accompanied by symptoms such as nasal congestion, runny nose, and diarrhea. Severe cases usually develop dyspnea after one week. In severe cases, acute respiratory distress syndrome, septic shock, refractory metabolic acidosis, and coagulation dysfunction occur rapidly. Some patients only show low fever and mild fatigue, without pneumonia manifestations, and mostly recover after one week. Laboratory tests: In the early stage of the disease, the total white blood cell count is normal or decreased, or the lymphocyte count is reduced; liver enzymes, muscle enzymes, and myoglobin increase in some patients, and C-reactive protein and erythrocyte sedimentation rate increase in most patients. Chest imaging shows multiple small patchy shadows and interstitial changes in the early stage, which are obvious in the outer zones of the lungs. Subsequently, multiple ground-glass shadows and infiltration shadows in both lungs develop, and lung consolidation may occur in severe cases. Real-time fluorescence RT-PCR detection of 2019-nCoV nucleic acid is positive in specimens such as sputum, throat swabs, and lower respiratory tract secretions. Clinical classification: I. Common type: It has symptoms such as fever and respiratory tract, and pneumonia manifestations can be seen on imaging. II. Severe type: Meeting any of the following criteria: 1. Respiratory distress, RR≥30 times / min; at rest, finger oxygen saturation ≤93%; arterial oxygen partial pressure (PaO2) / inspired oxygen concentration (FiO2) ≤300 mmHg). III. Critical type: Respiratory failure occurs and mechanical ventilation is required; shock occurs; combined with other organ failure and requires ICU monitoring and treatment. Treatment: 1. General treatment: Stay in bed, monitor vital signs and finger oxygen saturation, provide supportive and symptomatic treatment, ensure calorie intake, and maintain the stability of the internal environment such as water, electrolyte, and acid-base balance. 2. Oxygen therapy: Oxygen therapy should be carried out immediately for those with hypoxemia. The oxygenation maintenance goal: For non-pregnant adult patients, SpO2≥90%, and for pregnant patients, SpO2≥92-95%. 3. Antiviral treatment: α-Interferon aerosol inhalation can be tried (5 million U for adults each time, added to 2 ml of sterile injection water, twice a day); lopinavir / ritonavir (200 mg / 50 mg per capsule), 2 capsules each time, twice a day. 4. Antibacterial drug treatment: Avoid blindly or inappropriately using antibacterial drugs, especially the combined use of broad-spectrum antibacterial drugs. 5. Other treatment measures: Glucocorticoids can be used short-term as appropriate according to the degree of dyspnea and chest imaging progression of the patient: The dose is methylprednisolone 1-2 mg / kg.d, and Xuebijing 100 ml / d can be given intravenously, twice a day; intestinal microecological regulators can be used to maintain the balance of intestinal microecology. COVID-19 is still raging globally. However, there is still no effective treatment or preventive drug. Although some drugs that can be used to treat COVID-19 have been recommended globally, they are basically emergency drugs or compassionate use drugs, and there are still many deficiencies. For example, broad-spectrum antiviral drugs have no obvious activity against COVID-19, and many drugs for symptomatic treatment of viral pneumonia have poor effects. There are also many drugs that can inhibit the virus but have obvious toxicity. Therefore, there is an urgent need for drugs that are safe and effective in treating COVID-19. This invention is an improved invention based on the patent disclosed in CN1194752C, and the content recorded in this patent document is hereby incorporated by reference in its entirety. The above patent does not disclose the application of the pharmaceutical composition of the present invention in the prevention and treatment of patients with pneumonia caused by novel coronavirus infection. Summary of the Invention The inventors of the present invention unexpectedly found in the research that the pharmaceutical composition of the present invention can effectively prevent and treat pneumonia caused by novel coronavirus infection, and the pharmaceutical composition is made of the following raw materials by weight: Based on this discovery, in the first aspect, the present invention provides an application of a pharmaceutical composition in the preparation of a drug for preventing and treating pneumonia caused by novel coronavirus infection, and the pharmaceutical composition is made of the following raw materials by weight: The weight ratio of the raw materials of the pharmaceutical composition of the present invention is preferably: The weight ratio of the raw materials of the pharmaceutical composition of the present invention is also preferably: The weight ratio of the raw materials of the pharmaceutical composition of the present invention is also preferably: The weight ratio of the raw materials of the pharmaceutical composition of the present invention is also preferably: The active ingredient of the pharmaceutical composition of the present invention can be prepared by a method comprising the following steps: (1) Weigh the Chinese medicinal materials according to the weight ratio of the raw materials, and perform cleaning and selection; (2) Cut Pogostemon cablin into pieces, add 5-8 times the amount of water to extract the volatile oil, the extraction time is 4 hours, collect the volatile oil and set aside; after filtering the extraction solution, discard the residue and set aside the filtrate; (3) Forsythia suspensa, Ephedra carbonata, Houttuynia cordata, and Rheum palmatum are extracted twice with 6-10 times the amount of 50-90% ethanol for 1-3 hours each time. The extraction solutions are combined and filtered, the ethanol is recovered, and the filtrate is set aside; (4) Flos Lonicerae, Gypsum Fibrosum, Radix Isatidis, Dryopteris Crassirhizoma, Glycyrrhiza Uralensis Fisch., Rhodiola Rosea, add 7 - 11 times the amount of water and decoct until boiling, add Semen Armeniacae Amarum (fried), decoct 2 times, 0.5 - 2.5 hours each time, combine and filter the extraction liquid, combine the obtained filtrate with the filtrate after extracting essential oil from Pogostemon Cablin in step (2), concentrate to a clear paste with a relative density of 1.10 - 1.15 measured at 60 °C, add ethanol, adjust the alcohol concentration to 70%, refrigerate and stand, filter, recover ethanol until there is no alcohol smell, and obtain a clear paste for standby; (5) Combine the clear paste obtained in step (4) with the ethanol extract obtained in step (3), concentrate to a clear paste with a relative density of 1.15 - 1.20 measured at 60 °C, dry to obtain dry paste powder for standby; (6) Mix the dry paste powder obtained in step (5), the essential oil obtained in step (2) and menthol to prepare the active ingredient of the pharmaceutical composition. The dosage form of the drug of the present invention can be in the form of capsules, tablets, powders, granules, oral liquids, soft capsules, pills, tinctures, syrups, suppositories, gels, sprays or injections. To enable the above dosage forms to be realized, it is preferred to add pharmaceutically acceptable excipients when preparing these dosage forms, such as: fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives, matrices, etc. Fillers include: starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose, etc.; disintegrants include: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linked carboxymethyl cellulose sodium, etc.; lubricants include: magnesium stearate, sodium lauryl sulfate, talc powder, silicon dioxide, etc.; suspending agents include: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methylcellulose, etc.; binders include, starch paste, polyvinylpyrrolidone, hydroxypropyl methylcellulose, etc.; sweeteners include: sodium saccharin, aspartame, sucrose, sodium cyclamate, glycyrrhetinic acid, etc.; flavoring agents include: sweeteners and various flavors; preservatives include: parabens, benzoic acid, sodium benzoate, sorbic acid and its salts, benzalkonium bromide, chlorhexidine acetate, eucalyptus oil, etc.; matrices include: PEG6000, PEG4000, beeswax, etc. Among them, capsules can be prepared by a method including the following steps: (1) Weigh traditional Chinese medicinal materials according to the weight ratio of raw medicinal materials, and perform cleaning and selection; (2) Crush Pogostemon Cablin, add 5 - 8 times the amount of water to extract essential oil, the oil extraction time is 4 hours, collect the essential oil for standby; after filtering the extraction liquid, discard the residue and keep the filtrate for standby; (3) Forsythia Suspensa, Ephedra Praeparata, Houttuynia Cordata Thunb., Rheum Palmatum L., extract 2 times with 6 - 10 times the amount of 50 - 90% ethanol, 1 - 3 hours each time, combine and filter the extraction liquid, recover ethanol, and keep the filtrate for standby; (4) Flos Lonicerae, Gypsum Fibrosum, Radix Isatidis, Dryopteris Crassirhizoma, Glycyrrhiza Uralensis Fisch., Rhodiola Rosea, add 7 - 11 times the amount of water and decoct until boiling, add Semen Armeniacae Amarum (parched), decoct twice, each time for 0.5 - 2.5 hours, combine the extraction liquids and filter, combine the obtained filtrate with the filtrate after extracting the volatile oil from Pogostemon Cablin in step (2), concentrate to a clear paste with a relative density of 1.10 - 1.15 measured at 60°C, add ethanol, adjust the alcohol concentration to 70%, refrigerate and stand, filter, recover ethanol until there is no alcohol smell, obtain a clear paste for standby; (5) Combine the clear paste obtained in step (4) with the ethanol extract obtained in step (3), concentrate to a clear paste with a relative density of 1.15 - 1.20 measured at 60°C, dry to obtain dry paste powder for standby; (6) Add appropriate pharmaceutically acceptable excipients to the dry paste powder obtained in step (5) to prepare granules; (7) Dissolve Menthol and the volatile oil obtained in step (2) in ethanol, spray it into the granules obtained in step (6), seal, mix evenly, fill into capsules to obtain the product. Among them, the preparation method of the granule can be a method including the following steps: (1) Weigh traditional Chinese medicinal materials according to the weight ratio of the raw materials, carry out cleaning and selection, and break them as appropriate; (2) Break Pogostemon Cablin, add 5 - 8 times the amount of water to extract the volatile oil, the extraction time is 4 hours, collect the volatile oil for standby; after filtering the extraction liquid, discard the residue and reserve the filtrate; (3) Forsythia suspensa, Ephedra Praeparata, Houttuynia Cordata Thunb., Rheum Palmatum L., extract with 6 - 10 times the amount of 50 - 90% ethanol twice, each time for 1 - 3 hours, combine the extraction liquids and filter, recover ethanol, and reserve the filtrate; (4) Flos Lonicerae, Gypsum Fibrosum, Radix Isatidis, Dryopteris Crassirhizoma, Glycyrrhiza Uralensis Fisch., Rhodiola Rosea, add 7 - 11 times the amount of water and decoct until boiling, add Semen Armeniacae Amarum (parched), decoct twice, each time for 0.5 - 2.5 hours, combine the extraction liquids and filter, combine the obtained filtrate with the filtrate after extracting the volatile oil from Pogostemon Cablin in step (2), concentrate to a clear paste with a relative density of 1.10 - 1.15 measured at 60°C, add ethanol, adjust the alcohol concentration to 70%, refrigerate and stand, filter, recover ethanol until there is no alcohol smell, obtain a clear paste for standby; (5) Combine the clear paste obtained in step (4) with the ethanol extract obtained in step (3), concentrate to a thick paste with a relative density of 1.15 - 1.20 measured at 60°C for standby; (6) Add appropriate pharmaceutically acceptable excipients to the thick paste obtained in step (5) to make granules; (7) Dissolve Menthol and the volatile oil obtained in step (2) in ethanol, spray it into the granules obtained in step (6), seal, mix evenly, and bag to obtain the product. The preferred preparation method of the granule is a method including the following steps: (1) Weigh traditional Chinese medicinal materials according to the weight ratio of the raw materials, carry out cleaning and selection, and break them as appropriate; (2)Crush Pogostemon cablin, add 6 times the amount of water to extract volatile oil for 4 hours, collect the volatile oil for standby; after filtering the extract, discard the residue and keep the filtrate for standby; (3)Forsythia suspensa, Ephedra preparata, Houttuynia cordata, and Rheum palmatum are extracted twice with 8 times the amount of 70% ethanol, for 2 hours for the first time and 1.5 hours for the second time. Combine and filter the extracts, recover the ethanol, and keep the filtrate for standby; (4)Flos Lonicerae, Gypsum Fibrosum, Radix Isatidis, Dryopteris crassirhizoma, Glycyrrhiza uralensis, and Rhodiola rosea are decocted with 9 times the amount of water until boiling, add Semen Armeniacae Amarum stir-fried and decoct twice, for 1.5 hours for the first time and 1 hour for the second time. Combine and filter the extracts, and combine the obtained filtrate with the aqueous filtrate after extracting the volatile oil from Pogostemon cablin in step (2), concentrate to a clear paste with a relative density of 1.10 - 1.15 measured at 60°C, add 95% ethanol, adjust the alcohol concentration to 70%, refrigerate and stand, filter, and recover the ethanol until there is no alcohol smell to obtain a clear paste filtrate; (5)Combine the clear paste obtained in step (4) with the ethanol extract obtained in step (3), concentrate to a thick paste with a relative density of 1.15 - 1.20 measured at 60°C for standby; (6)Add appropriate pharmaceutically acceptable excipients to the thick paste obtained in step (5) to prepare granules, size the granules, and keep for standby; (7)Sieve out the fine powder from the granules obtained in step (6), dissolve menthol and the volatile oil obtained in step (2) in ethanol, spray it into the fine powder, mix evenly, then mix evenly with the granules obtained in step (6), seal for half an hour, bag, and obtain the product. To prepare other dosage forms of the drug of the present invention, the raw materials can be weighed proportionally and prepared by conventional preparation methods. For example, according to the preparation process described in Fan Biting's "Chinese Pharmacy" (the first edition published by Shanghai Science and Technology Press in December 1997), it can be made into conventional dosage forms acceptable in pharmacy. The present invention also provides the use of the pharmaceutical composition in the preparation of a drug for improving shortness of breath and / or dyspnea. The present invention also provides the use of the pharmaceutical composition in the preparation of a drug for improving fever, cough, and fatigue. The present invention also provides the use of the pharmaceutical composition in the preparation of a drug for improving chest tightness. The present invention also provides the use of the pharmaceutical composition in the preparation of a drug for improving pulmonary moist rales. The present invention also provides the use of the pharmaceutical composition in the preparation of a drug for inhibiting the elevation of cytokines and chemokines. In the above applications, the cytokines and chemokines are preferably selected from TNF-α, IL-6, CCL-2 / MCP-1, and CXCL-10 / IP-10. Description of the Drawings: Figure 1: Showing the inhibitory effect of the pharmaceutical composition of the present invention - the granules prepared in Example 4 (hereinafter referred to as LHQW or LH) on the cytopathic effect caused by common coronavirus (HCoV-229E) and novel coronavirus (2019-nCoV); Figure 2: Showing the electron microscopy pictures of the inhibitory effect of LHQW on the infection of Vero E6 cells by HCoV-229E and 2019-nCoV; Figure 3: Showing the inhibitory effect of LHQW on the mRNA expression of inflammatory factors caused by the infection of Huh-7 cells by 2019-CoV; Figure 4: Showing the cytotoxicity of LHQW and remdesivir to Vero E6 cells; Figure 5: Showing the inhibitory effect of LHQW and remdesivir on SARS-CoV-2 virus; Figure 6: Showing the typical coronavirus morphology observed under the electron microscope after treatment with LHQW and remdesivir; Figure 7: Showing the role of LHQW in inhibiting the expression of cytokines and chemokines induced by SAR2-CoV-2. Detailed implementation manners The following examples are used to illustrate the preparation of the pharmaceutical composition of the present invention, but it should be understood that they cannot limit the scope of the present invention. Example 1 Prescription: Preparation method: (1) Weigh the Chinese medicinal materials according to the above prescription and perform cleaning and selection; (2) Cut Pogostemon cablin into pieces, add 6 times the amount of water to extract the volatile oil, with an extraction time of 4 hours, collect the volatile oil and reserve it; after filtering the extraction solution, discard the residue and reserve the filtrate; (3) Forsythia suspensa, Ephedra carbonata, Houttuynia cordata, and Rheum palmatum are extracted twice with 8 times the amount of 70% ethanol, the first time for 2 hours and the second time for 1.5 hours. Combine and filter the extraction solutions, recover the ethanol, and reserve the filtrate; (4) Flos Lonicerae, Gypsum fibrosum, Radix Isatidis, Dryopteris crassirhizoma, Glycyrrhiza uralensis, and Rhodiola rosea are added with 9 times the amount of water and boiled until boiling, then stir-fried Armeniaca vulgaris var. ansu is added and boiled twice, the first time for 1.5 hours and the second time for 1 hour. Combine and filter the extraction solutions, and combine the obtained filtrate with the filtrate obtained after extracting the volatile oil of Pogostemon cablin in step (2), concentrate it into a clear paste with a relative density of 1.10 - 1.15 measured at 60°C, add ethanol to adjust the alcohol concentration to 70%, refrigerate and stand for 24 hours, filter, and recover the ethanol until there is no alcohol smell to obtain a clear paste for reserve; (5) Combine the clear paste obtained in step (4) with the ethanol extraction solution obtained in step (3), concentrate it to a clear paste with a relative density of 1.15 - 1.20 measured at 60°C, and perform spray drying to obtain a dry paste powder for reserve; (6) Add 142 grams of starch to the dry extract powder obtained in step (5), and prepare granules with 85% ethanol; (7) Dissolve menthol and the volatile oil obtained in step (2) in ethanol, spray it into the granules obtained in step (6), seal, mix well, and fill into 1000 capsules to obtain the product. Example 2 Prescription: Preparation method: (1) Weigh the Chinese medicinal materials according to the above prescription and perform cleaning and selection; (2) Cut Pogostemon cablin into pieces, add 5 times the amount of water to extract the volatile oil for 4 hours, collect the volatile oil for later use; after filtering the extraction liquid, discard the residue and reserve the filtrate; (3) Forsythia suspensa, Ephedra carbonata, Houttuynia cordata, and Rheum palmatum are extracted twice with 6 times the amount of 50% ethanol, 1 hour for the first time and 2.5 hours for the second time. Combine and filter the extraction liquids, recover the ethanol, and reserve the filtrate; (4) Flos Lonicerae, Gypsum Fibrosum, Radix Isatidis, Dryopteris crassirhizoma, Glycyrrhiza uralensis, and Rhodiola rosea are added with 7 times the amount of water and boiled until boiling, then add Semen Armeniacae Amarum Praeparatum and decoct twice, 1.5 hours for the first time and 1 hour for the second time. Combine and filter the extraction liquids, and combine the obtained filtrate with the filtrate obtained after extracting the volatile oil from Pogostemon cablin in step (2), concentrate it into a clear paste with a relative density of 1.10 - 1.15 measured at 60 °C, add ethanol to adjust the alcohol concentration to 70%, refrigerate for 24 hours, filter, and recover the ethanol until there is no alcohol smell to obtain a clear paste for later use; (5) Combine the clear paste obtained in step (4) with the ethanol extract obtained in step (3), concentrate it into a clear paste with a relative density of 1.15 - 1.20 measured at 60 °C, and perform spray drying to obtain dry extract powder for later use; (6) Add 151 grams of starch to the dry extract powder obtained in step (5), and prepare granules with 85% ethanol; (7) Dissolve menthol and the volatile oil obtained in step (2) in ethanol, spray it into the granules obtained in step (6), seal, mix well, and press into tablets to obtain 935 tablets. Example 3 Prescription: Preparation method: (1) Weigh the Chinese medicinal materials according to the above prescription and perform cleaning and selection; (2) Cut Pogostemon cablin into pieces, add 6 times the amount of water to extract the volatile oil for 4 hours, collect the volatile oil for later use; after filtering the extraction liquid, discard the residue and reserve the aqueous extract; (3) Forsythia suspensa, Ephedra herba preparata, Houttuynia cordata, Rheum palmatum are extracted twice with 8 times the amount of 70% ethanol, for 2 hours for the first time and 1.5 hours for the second time. The extraction solutions are combined and filtered, the ethanol is recovered, and the filtrate is reserved for use; (4) Flos Lonicerae, Gypsum fibrosum, Radix Isatidis, Dryopteris crassirhizoma, Glycyrrhiza uralensis, Rhodiola rosea are decocted with 9 times the amount of water until boiling, and semen Armeniacae amarum praeparatum is added and decocted twice, for 1.5 hours for the first time and 1 hour for the second time. The extraction solutions are combined and filtered, and the obtained filtrate is combined with the aqueous extraction solution obtained after extracting the volatile oil from Pogostemon cablin in step (2), and concentrated into a clear extract with a relative density of 1.10 - 1.15 measured at 60°C. 95% ethanol is added to adjust the ethanol concentration to 70%, and it is refrigerated and left for 24 hours, then filtered, and the ethanol is recovered until there is no ethanol smell to obtain a clear extract for standby; (5) The clear extract obtained in step (4) is combined with the ethanol extract obtained in step (3), concentrated to a thick extract with a relative density of 1.25 - 1.30 measured at 60°C, and spray-dried to obtain dry extract powder for standby; (6) The dry extract powder obtained in step (5), the volatile oil obtained in step (2) and menthol are made into pills by a conventional method to obtain 905 pills. Example 4: The raw material drug formula is: Preparation method: (I) Extraction process: (1) Weigh the Chinese medicinal materials according to the above prescription amount, perform cleaning and selection, and break them as appropriate; (2) Pogostemon cablin is extracted with 6 times the amount of water to obtain volatile oil, and the extraction time is 4 hours. The volatile oil is collected, and the oil yield is 0.33%. The extraction solution is filtered and reserved for use, and the residue is discarded, and the aqueous extraction solution is reserved for use; (3) Forsythia suspensa, Ephedra herba preparata, Houttuynia cordata, Rheum palmatum are extracted twice with 8 times the amount of 70% ethanol, for 2 hours for the first time and 1.5 hours for the second time. The extraction solutions are filtered, the filtrates are combined, and the ethanol is recovered until there is no ethanol smell for standby; (4) Flos Lonicerae, semen Armeniacae amarum praeparatum, Gypsum fibrosum, Radix Isatidis, Dryopteris crassirhizoma, Glycyrrhiza uralensis, Rhodiola rosea are decocted with 9 times the amount of water until boiling, and semen Armeniacae amarum praeparatum is added and decocted twice, for 1.5 hours for the first time and 1 hour for the second time. The extraction solutions are filtered, the filtrates are combined and at the same time the aqueous solution after extracting the volatile oil from Pogostemon cablin in step (2) is added, and concentrated into a clear extract with a relative density of 1.10 - 1.15 measured at 60°C. 95% ethanol is added while stirring until the ethanol concentration is 70%, refrigerated and left for 24 hours, filtered, and the filtrate is recovered until there is no ethanol smell and combined with the ethanol extract obtained in step (3), and concentrated into a thick extract with a relative density of 1.15 - 1.20 measured at 60°C for standby; (II) Preparation process: The preparation formula is: 335.5 g of the thick extract obtained in step (4) and 5 g of menthol 0.2 ml of Pogostemon oil obtained in step (2), 342.5 g of powdered sugar, 514.0 g of dextrin (5) Granulation: Mix the powdered sugar and dextrin evenly according to the above formula, use the thick paste obtained in step (4) as a binder to make soft materials, granulate through a 14-mesh sieve, dry at 60 - 65 °C, and size through a 10-mesh sieve; (6) Sub-packaging: Sieve out an appropriate amount of fine powder. Add menthol and Pogostemon volatile oil in appropriate amounts to ethanol according to the prescription amount, dissolve, spray it into the fine powder sieved out in the sizing step of step (5), mix evenly, and mix evenly with the granules obtained in step (5). Seal for half an hour, bag it, and it is ready. The above prescription can make 1000 g of granules. Experimental example To confirm the efficacy of the pharmaceutical composition of the present invention in preventing and treating pneumonia caused by novel coronavirus infection, the granules prepared by the method of Example 4 (hereinafter referred to as LHQW or the pharmaceutical of the present invention or the pharmaceutical composition of the present invention) were used for the following in vitro research and clinical trial research: Experimental example 1: In vitro cell research Professor Yang Zifeng's team at the State Key Laboratory of Respiratory Diseases, Guangzhou Medical University, conducted a cell model study on the anti-SARS-CoV-2 and anti-inflammatory activities of LHQW and found that LHQW has good inhibitory effects on cytopathic effects caused by common coronavirus (HCoV-229E) and novel coronavirus (2019-nCoV) infections (Figure 1), and the IC 50 values are 338.74 and 414.02 μg / mL respectively, and the SI values are 3.47 and 2.89 respectively (Table 1). Table 1 In vitro inhibitory effects of LHQW on HCoV-229E and 2019-nCoV TC 50 : Median toxic concentration of the drug to cells IC 50 : Median pharmacodynamic concentration of the drug SI: Selectivity index (TC 50 / IC 50 ) Transmission electron microscopy analysis found that normal cells had intact morphology and no virus particles were observed outside or inside the cells; a large number of virus particles could be seen in the cell membrane, cytoplasm, and vesicles of virus-infected cells; the number of intracellular virus particles in cells treated with LHQW was less than that in virus-infected cells, and some virus particles were slightly deformed (see Figure 2). After Huh-7 cells were infected with 2019-CoV, different concentrations of LHQW were added. After 48 hours, cell mRNA was extracted, reverse transcribed into cDNA, and the expression of inflammatory factors was detected by RT-qPCR. The results showed that the two drugs had a significant inhibitory effect on the mRNA expression of inflammatory factors such as TNF-α, IL-6, CCL2 / MCP-1, and CXCL-10 / IP-10, showing a dose-dependent relationship (see Figure 3). Experimental Example 2: Clinical Study 1 I. Materials and Methods 1. Subject Selection From clinical cases, those who met the diagnostic criteria for pneumonia caused by novel coronavirus infection and were determined to be positive for novel coronavirus nucleic acid by nucleic acid testing of specimens such as sputum, throat swabs, and lower respiratory tract secretions were collected. Inclusion Criteria: Adult patients aged 18 and above who met the diagnostic criteria for pneumonia caused by novel coronavirus infection and had a body temperature > 37.2°C, and were ordinary type inpatients. Exclusion Criteria: (1) Patients with severe or critical pneumonia caused by novel coronavirus infection; (2) Acute respiratory diseases not caused by 2019-nCoV; (3) Any other chronic respiratory diseases, respiratory system bacterial infections such as suppurative tonsillitis, acute tracheo-bronchitis, sinusitis, otitis media, and other respiratory diseases that affect the evaluation of clinical trials; (4) Patients with asthma that requires daily treatment, and those with underlying lung diseases such as severe interstitial lung lesions and bronchiectasis confirmed by chest CT; (5) Patients with underlying diseases such as severe primary immunodeficiency diseases, acquired immunodeficiency syndrome, congenital respiratory malformations, congenital heart diseases, and abnormal lung development. 2. Grouping Method: A. Test Drug Group: 21 cases, adult patients aged over 18 with a body temperature > 37.2°C, who met the diagnostic criteria for pneumonia caused by novel coronavirus infection and were ordinary type inpatients. They took the pharmaceutical composition of the present invention, and the treatment plan was conventional treatment (referring to the "Prevention and Control Plan for Pneumonia Caused by Novel Coronavirus Infection" issued by the National Health Commission) plus the pharmaceutical composition of the present invention, 1 bag / time, 3 times / day; taking age and body temperature as covariates, the propensity score value was calculated using a logistic regression model and matched in a 1:1 ratio. B. 21 matched patients were used as the control group, and the treatment plan was conventional treatment, and the conventional treatment was to give nutritional support treatment, symptomatic treatment, antiviral treatment, antibacterial drug treatment, etc. according to the condition monitoring. 3. Evaluation Indexes: Compare the disappearance rates of the main symptoms (fever, fatigue, cough), the time to disappearance of fever, and the disappearance rates of other single symptoms between the test drug group and the control group. 4. Statistical methods: Statistical analysis was performed using SAS 9.4 software. All statistical tests were two-sided, and a P value less than or equal to 0.05 was considered statistically significant for the tested differences. Descriptive analysis: For count data, the number of cases and the constituent ratio were used for description, and for measurement data, the mean and standard deviation were used for description. The t-test was used for between-group comparison of quantitative data, and the chi-square test or exact probability method was used for categorical data. II. Results 1. Baseline data A total of 42 confirmed common type patients with novel coronavirus pneumonia who met the requirements were included. In the experimental drug group, there were 16 males (76.2%) and 5 females (23.8%), with an average age of (57.1 ± 14.0) years old; in the control group, there were 12 males (57.1%) and 9 females (42.9%), with an average age of (55.4 ± 12.3) years old. For the baseline data of the two groups of patients, including age, gender, as well as body temperature, blood pressure, heart rate, respiration, past medical history, time from onset to diagnosis, etc., there was no statistically significant difference between the groups (P > 0.05), and they were comparable. See Table 2 for details. Table 2 Baseline data of the treatment group and the control group 2. Comparison of the disappearance rates of the main symptoms between the two groups: (1) Baseline data: There were 21 cases in the experimental drug group, among which 21 cases had fever (100%), 15 cases had cough (71.4%), and 12 cases had fatigue (57.1%); there were 21 cases in the control group, among which 21 cases had fever (100%), 18 cases had cough (85.7%), and 13 cases had fatigue (61.9%). There was no statistically significant difference between the groups (P > 0.05). (2) Treatment results: Compared with the control group, in the experimental drug group, 18 cases (85.7%) had the fever symptom disappear and 7 cases (46.7%) had the cough symptom disappear. There was a statistically significant difference between the groups (P < 0.05). See Table 3 for details. Table 3 Disappearance rates of the main symptoms of the treatment group and the control group 3. Comparison of the duration of fever between the two groups: There were 21 cases in the experimental drug group, and the duration of fever was (4.6 ± 3.2) d; there were 21 cases in the control group, and the duration of fever was (6.1 ± 3.1) d. There was no statistically significant difference between the groups (P = 0.218). 4. Comparison of the disappearance rates of other symptoms between the two groups: Compared with the control group, the disappearance rates of expectoration and shortness of breath symptoms in the treatment group were 64.3% and 77.8% respectively. There was a statistically significant difference between the groups (P < 0.05). See Table 4 for details. Table 4 Disappearance rates of other symptoms of the treatment group and the control group During the research process of the present invention, 42 confirmed patients with COVID-19 who had fever symptoms were enrolled, and at the same time, they were accompanied by varying degrees of symptoms such as cough, fatigue, expectoration, muscle pain, shortness of breath, sore throat, nausea, vomiting, loss of appetite, diarrhea, etc. During the treatment process, we were pleasantly surprised to find that the patients in the treatment group taking the granule of Example 4 of the pharmaceutical composition of the present invention could significantly relieve clinical symptoms such as fever, cough, expectoration, shortness of breath, etc. during the medication period, and the average time for the disappearance of fever was shortened by 1.5 days compared with the control group, which also showed the clinical advantages of this drug in improving fever symptoms. At the same time, this drug also showed a positive trend in improving symptoms such as fatigue, muscle pain, nasal congestion, and headache. The patients selected and enrolled in this study were mild to moderate COVID-19 patients, considering that mild to moderate patients can communicate and feedback the efficacy of medication better, which does not mean that severe patients cannot take it. Experimental Example 3: Clinical Research 2 1 Clinical Data 1.1 Diagnostic Criteria Referring to the diagnostic criteria for suspected cases in the "Diagnosis and Treatment Plan for COVID-19 (Trial Version 4)", if there is any one of the epidemiological histories of travel, residence, contact, and gathering, and the clinical manifestations are fever and / or respiratory symptoms, normal / reduced / lymphocyte count reduction in the early stage of white blood cell count, and any 2 of the NCP imaging features, it can be determined as a suspected case. 1.2 Inclusion Criteria Inpatients who meet the above diagnostic criteria for suspected cases, are over 18 years old, and have NCP imaging features. 1.3 Exclusion Criteria Confirmed patients with severe and critical COVID-19; patients with bronchial asthma; patients with basic lung diseases such as severe interstitial lung disease and bronchiectasis confirmed by chest X-ray computed tomography (CT); patients with underlying diseases such as severe immunodeficiency diseases, congenital respiratory malformations, congenital heart diseases, and abnormal lung development. 1.4 General Information 101 suspected patients were collected. Among them, 38 patients treated with conventional therapy were in the control group; 63 patients treated with conventional therapy combined with the drug of the present invention (LHQW) were in the treatment group. There were no statistically significant differences in the baseline data such as age, gender, body temperature, blood pressure, heart rate, respiration, past medical history, fever, fatigue, cough, conventional treatment, and main laboratory examination indicators between the two groups (P>0.05), and the test results were comparable. The general information of the patients in the treatment group and the control group is shown in Table 5. Table 5 Comparison of General Information between the Two Groups 2 Methods 2.1 Treatment Method The conditions of the two groups of patients were monitored, and nutritional support treatment, symptomatic treatment, antiviral treatment, antibacterial drug treatment, etc. were given. The main treatment drugs were moxifloxacin hydrochloride and sodium chloride injection, 0.4 g, once a day, produced by Chengdu Zhengkang Pharmaceutical Co., Ltd., batch number 3419111102; ganciclovir injection, 0.5 g, once a day, produced by Hubei Keyi Pharmaceutical Co., Ltd., batch number 191003; intravenous human immunoglobulin, 2.5 g, once a day, produced by Guizhou Taibang Biological Products Co., Ltd., batch number 201906026; ambroxol hydrochloride injection, 30 mg, twice a day, produced by Tianjin Pharmaceutical Group Co., Ltd., batch number 1906116; doxofylline for injection, 0.2 g, once a day, produced by Ruiyang Pharmaceutical Co., Ltd., batch number 19082116; methylprednisolone sodium succinate for injection, 40 mg, once a day, produced by Liaoning Heska Pharmaceutical Co., Ltd., batch number 20191027. Control group: Only the above treatment was given. Treatment group: On the basis of the above treatment, the drug of the present invention was combined, 6 g / bag, 1 bag each time, 3 times a day. The clinical data of the patients were collected 10 days after treatment 2.2 Observation Indicators and Methods 2.2.1 Comparison of the disappearance of the main symptoms of the two groups of patients: disappearance rate of (fever, fatigue, cough), fever disappearance time, and disappearance rate of other single symptoms and signs (muscle pain, expectoration, nasal congestion, runny nose, sore throat, shortness of breath, chest tightness, dyspnea, headache, nausea, vomiting, loss of appetite, diarrhea, moist rales), and the aggravation of the condition during the treatment process. 2.2.2 Safety evaluation: Blood routine, urine routine, stool routine, liver function, and renal function were detected before and after treatment. 2.3 Statistical Methods Statistical analysis was performed using SAS 9.4 software. All statistical tests were two-sided tests. The count data of descriptive analysis were described by the number of cases and the constituent ratio, and the measurement data were described by the mean ± standard deviation. The between-group comparison of measurement data was performed using the t-test, and the count data were performed using the chi-square test or the exact probability method. The fever duration was analyzed using the survival analysis method. A P value ≤ 0.05 was considered statistically significant. 3 Results 3.1 Comparison of the disappearance rates of the main symptoms of the two groups of patients Table 6 shows that compared with the control group, the disappearance of fever, cough, and fatigue symptoms in the treatment group was significantly better than that in the control group (all P < 0.05). Table 6 Comparison of the disappearance rates of the main symptoms of the two groups of patients 3.2 Comparison of the duration of fever in the two groups of patients There were 52 patients with fever in the treatment group, and the median duration of fever was 6 days; there were 23 patients with fever in the control group, and the median duration of fever was 7 days. There was no statistically significant difference between the two groups (P = 0.171). 3.3 Comparison of the disappearance rates of other symptoms and signs in the two groups of patients Table 7 shows that the disappearance rates of shortness of breath and moist rales in the treatment group were 68.2% and 56.0% respectively, which were significantly better than 20.0% and 20.0% in the control group (χ 2 = 9.817, 4.972), and the differences between the two groups were statistically significant (P < 0.05); there was no statistically significant difference in the disappearance rates of other symptoms between the two groups. Table 7 Comparison of the disappearance of other symptoms and signs in the two groups of patients 3.4 Worsening of the condition during the treatment process in the two groups of patients There were 63 cases in the treatment group, and 4 cases (6.4%) had their condition worsen during the treatment process; there were 38 cases in the control group, and 6 cases (15.8%) had their condition worsen during the treatment process. There was no statistically significant difference between the two groups (P > 0.05). 3.5 Safety analysis During the treatment process, there were no abnormal conditions related to the drug of the present invention in the routine blood tests, liver and kidney function and other laboratory tests of the treatment group, and no adverse reactions of the drug of the present invention were seen, and the clinical application was safe. Experimental example 4: Clinical study 3 1 Subjects and methods 1.1 Research subjects The clinical data of patients who met the diagnostic criteria for the common type of "Diagnosis and Treatment Plan for Pneumonia Caused by Novel Coronavirus Infection (Trial Version 5)" and were determined to be positive for NCP by nucleic acid testing of specimens such as sputum, throat swabs, and lower respiratory tract secretions were collected. There were 54 patients who received the drug of the present invention (LHQW) combined with conventional treatment (nutrition support treatment, symptomatic treatment, antiviral treatment, antibacterial drug treatment, etc. according to the condition monitoring). 1.2 Research methods The clinical data of 54 patients with common type of NCP were analyzed, including the disappearance rates of the main symptoms (fever, fatigue, cough) on the 3rd, 5th, and 7th days, the number of days of fever disappearance, and the disappearance rates of other symptoms and signs, etc. were retrospectively summarized and analyzed. At the same time, the main symptoms were scored 0 for "none" and 1 for "present", and if the symptom score reduction rate > 30% was judged as treatment effective, and ≤ 30% was judged as treatment ineffective, and the treatment effective rate of all patients after 7 days of treatment was analyzed. 2 Results 2.1 General information: Among the 54 inpatients, the age ranged from 25 to 95 years old, with an average of (60.1 ± 16.98) years; among them, 29 were male (53.7%), and 25 were female (46.3%); the average body temperature was (37.93 ± 0.93) °C, and the median temperature was 38.05 °C; the highest body temperature before diagnosis was (38.54 ± 0.60) °C; the average heart rate was (87.9 ± 11.80) beats / min, the median number was 85.5 beats / min, and the highest was 112 beats / min; the average respiratory rate was (21.1 ± 3.78) breaths / min, the median number was 20.0 breaths / min, and the highest was 30.0 breaths / min; 21 cases (38.9%) had a history of hypertension, 7 cases (13.0%) had a history of coronary heart disease, 10 cases (18.5%) had a history of diabetes, and 10 cases (18.5%) had a history of cerebral infarction; Laboratory tests: Among the 54 patients, 31 cases (64.6%) had white blood cells within the normal range, 9 cases (18.8%) were lower than the normal value, and 8 cases (16.7%) were higher than the normal value; 25 cases (52.1%) had neutrophils within the normal range, and 23 cases (47.9%) were higher than the normal value; 14 cases (29.2%) had lymphocytes within the normal range, and 34 cases (70.8%) were lower than the normal value; the hypersensitive C-reactive protein was higher than the normal value in all patients (100%); the average number of days for all patients to use the drug of the present invention was (8.0 ± 4.10) days, the median number of days was 7.0 days, the shortest was 1.0 day, and the longest was 16.0 days. Table 8 General information of NCP common type patients 2.2 Disappearance rate of main symptoms (fever, fatigue, cough) ① Before treatment: Among the 54 patients, 40 cases (74.1%) had fever, 37 cases (68.5%) had fatigue, and 30 cases (55.6%) had cough; ② After 3 days of treatment, 19 cases (disappearance rate 47.5%) had the fever symptom disappear, 13 cases (disappearance rate 35.1%) had the fatigue symptom disappear, and 6 cases (disappearance rate 20.0%) had the cough symptom disappear; ③ After 5 days of treatment, 25 cases (disappearance rate 62.5%) had the fever symptom disappear, 22 cases (disappearance rate 59.5%) had the fatigue symptom disappear, and 15 cases (disappearance rate 50.0%) had the cough symptom disappear; ④ After 7 days of treatment, 32 cases (disappearance rate 80.0%) had the fever symptom disappear, 28 cases (disappearance rate 75.7%) had the fatigue symptom disappear, and 23 cases (disappearance rate 76.7%) had the cough symptom disappear. The results are shown in Table 9. Table 9 Disappearance rate of main symptoms of NCP common type patients 2.3 Days when the main symptoms (fever, fatigue, cough) disappeared ① The average number of days when the fever symptom disappeared was (3.6 ± 2.14) days, the median number of days was 3.0 days, the shortest was 1.0 day, and the longest was 8.0 days; ② The average number of days when the fatigue symptom disappeared was (4.1 ± 2.58) days, the median number of days was 4.0 days, the shortest was 1.0 day, and the longest was 12.0 days; ③ The average number of days when the cough symptom disappeared was (5.3 ± 2.63) days, the median number of days was 5.0 days, the shortest was 1.0 day, and the longest was 12.0 days. 2.4 Disappearance rates of other symptoms and signs ① Before treatment: Among 54 patients, 13 had chest tightness (24.1%), 8 had dyspnea (14.8%), 10 had loss of appetite (18.5%), and 19 had moist rales (35.2%); ② After 7 days of treatment: For the chest tightness symptom, there were 2 cases, and 11 cases disappeared (disappearance rate 84.6%); for the dyspnea symptom, there were 0 cases, and 8 cases disappeared (disappearance rate 100%); for the loss of appetite symptom, there were 6 cases, and 4 cases disappeared (40.0%); for the moist rales sign, there were 2 cases, and 17 cases disappeared (disappearance rate 89.5%). The results are shown in Table 10. Table 10 Disappearance rates of other symptoms and signs in patients with common type of NCP 2.5 Treatment effectiveness rate After 3 days of treatment, 23 out of 54 NCP patients were effective (effectiveness rate 46.9%); after 5 days of treatment, 34 were effective (effectiveness rate 69.4%); after 7 days of treatment, 40 were effective (effectiveness rate 81.6%). The results are shown in Table 11. Table 11 Treatment effectiveness rates of patients with common type of NCP 2.6 Safety analysis After analysis, during the application of the drug of the present invention in combination with conventional treatment, no abnormal conditions related to the drug of the present invention were found in laboratory tests such as blood routine, liver and kidney functions, etc., and no adverse reactions of the drug of the present invention were seen, and the clinical application is safe. Experimental example 5: 1 Subjects and methods 1.1 Research subjects Patient cases were collected, and the patients were determined to be positive for NCP by nucleic acid testing of specimens such as sputum, throat swabs, and lower respiratory tract secretions. 1.2 Inclusion criteria Patients aged between 18 and 70 years old, meeting the diagnostic criteria for common type of NCP in the "Diagnosis and Treatment Plan for Pneumonia Caused by Novel Coronavirus (Trial Version 5)" and hospitalized for more than 6 days. 1.3 Exclusion criteria: ① Severe and critical NCP patients; ② Any other chronic respiratory diseases, respiratory system bacterial infections such as suppurative tonsillitis, acute tracheo-bronchitis, sinusitis, otitis media and other respiratory diseases affecting the assessment; ③ Patients with underlying diseases such as severe interstitial lung disease, bronchiectasis, primary immunodeficiency disease, congenital respiratory malformation, congenital heart disease, abnormal lung development, etc.; ④ Patients with severe liver diseases (aspartate aminotransferase AST, alanine aminotransferase ALT exceeding 5 times the upper limit of the normal value), or those with severe renal insufficiency or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis; ⑤ Malignant tumors, hematological diseases, cachexia, active bleeding, severe malnutrition, HIV, etc. with multiple metastases and unable to perform resection, or those suffering from severe neurological and mental diseases, etc. 1.4 Grouping method: Collect patients who meet the inclusion criteria. Among them, patients treated with the drug of the present invention for 5 days or more are included in the statistics, a total of 51 cases. Using age, body temperature, and course of disease as covariates, the propensity score value is calculated using the Logistic regression model; in addition, 51 cases of patients are matched as the control group at a ratio of 1:1 and receive conventional treatment. 1.5 Treatment method: Control group: Receive conventional treatment, that is, simple nutritional support treatment, symptomatic treatment, antiviral treatment, and antibacterial drug treatment; Treatment group: On the basis of conventional treatment, combine the drug of the present invention (LHQW), 6 g / bag, 1 bag each time, 3 times a day. Collect the clinical data of patients after 7 days of treatment. 1.6 Observation indicators: Analyze the clinical data of the two groups of patients, including the disappearance rate and disappearance days of the main symptoms (fever, fatigue, cough), as well as the disappearance rate of other symptoms and signs, the effective rate of the main symptoms, the improvement rate of CT, and the rate of clinical progression to severe cases, etc. 1.7 Evaluation criteria: ① Symptom disappearance rate: Symptom disappearance rate = number of cases with symptoms disappeared after treatment / total number of cases × 100%; ② Effective rate of main symptoms: For the main symptoms (fever, fatigue, cough), "none" is scored 0, "yes" is scored 1, symptom score reduction rate = (score before treatment - score after treatment) / score before treatment × 100%. When the symptom score reduction rate > 30%, it is judged as effective treatment, and when ≤ 30%, it is judged as ineffective treatment; Treatment effective rate = number of cases judged as effective after treatment / total number of cases × 100%. ③ CT improvement rate = number of cases with improved pulmonary imaging (CT) compared with before after treatment / total number of cases × 100%; ④ Rate of clinical progression to severe cases: Refer to the severe diagnosis criteria in the "Diagnosis and Treatment Plan for Pneumonia Caused by Novel Coronavirus (Trial Version 5)"
[0015] , Rate of clinical progression to severe cases = number of cases converted from ordinary type to severe type / total number of cases × 100%. 1.8 Statistical methods Statistical analysis was performed using SAS 9.4 software. All statistical tests were two-sided. For descriptive analysis, count data were described by the number of cases and the constituent ratio, and measurement data were described by the mean ± standard deviation. The t-test was used for comparison of measurement data between groups, and the chi-square test or exact probability method was used for count data. The survival analysis method was used for the duration of fever. A P value ≤ 0.05 was considered statistically significant. 2 Results 2.1 General information A total of 102 confirmed patients with the ordinary type who met the requirements were collected, including 51 cases in the treatment group and 51 cases in the control group. In the treatment group, there were 26 males (51.0%) and 25 females (49.0%), with an average age of (55.5 ± 12.3) years, an average body temperature of (38.44 ± 0.63) °C; systolic blood pressure of (122.6 ± 11.9) mmHg, diastolic blood pressure of (75.0 ± 9.2) mmHg; average heart rate of (89.0 ± 11.6) beats / min, and average respiration of (19.8 ± 2.4) times / min. There were 15 cases (29.4%) with a history of hypertension, 5 cases (9.8%) with a history of coronary heart disease, 4 cases (7.8%) with a history of diabetes, and 3 cases (5.9%) with a history of cerebral infarction; laboratory tests showed that the blood white blood cell count decreased in 13 cases (25.5%), lymphocytes decreased in 20 cases (39.2%), high-sensitivity C-reactive protein increased in 40 cases (78.4%), erythrocyte sedimentation rate increased in 20 cases (39.2%), and procalcitonin increased in 16 cases (31.4%); In the control group of 51 cases, there were 27 males (52.9%) and 24 females (47.1%), with an average age of (55.8 ± 11.6) years, an average body temperature of (38.33 ± 0.64) °C, systolic blood pressure of (127.0 ± 16.3) mmHg, diastolic blood pressure of (74.8 ± 10.3) mmHg; average heart rate of (88.7 ± 13.4) beats / min, and average respiration of (20.0 ± 2.8) times / min. There were 17 cases (33.3%) with a history of hypertension, 2 cases (3.9%) with a history of coronary heart disease, 4 cases (7.8%) with a history of diabetes, and 6 cases (11.8%) with a history of cerebral infarction; laboratory tests showed that the blood white blood cell count decreased in 16 cases (31.4%), lymphocytes decreased in 24 cases (47.1%), high-sensitivity C-reactive protein increased in 42 cases (82.4%), erythrocyte sedimentation rate increased in 24 cases (47.1%), and procalcitonin increased in 17 cases (33.3%). There were no statistically significant differences in the baseline data between the two groups of patients in terms of age, gender, body temperature, blood pressure, heart rate, respiration, previous medical history, laboratory test results, etc. (P > 0.05), and they were comparable. The results are shown in Table 12. Table 12 Comparison of general information of two groups of patients Note: Male, past medical history, and laboratory test results are count data, and chi-square test is used for comparison; the rest are measurement data, and t-test is used for comparison. 1 mmHg ≈ 0.133 kPa. 2.2 Comparison of the disappearance rates of the main symptoms in the two groups of patients ① Baseline data: There were 51 cases in the treatment group, including 43 cases (84.3%) with fever, 31 cases (60.8%) with fatigue, and 37 cases (72.6%) with cough; there were 51 cases in the control group, including 41 cases (80.4%) with fever, 35 cases (68.6%) with fatigue, and 39 cases (76.5%) with cough; there was no statistically significant difference in the comparison between groups. ② After 7 days of treatment, compared with the control group, 36 cases (83.7%) of the treatment group had the fever symptom disappeared, which was significantly better than 25 cases (61.0%) of the control group (x 2 = 5.461, P = 0.019); 19 cases (61.3%) of the treatment group had the fatigue symptom disappeared, which was significantly better than 12 cases (34.3%) of the control group (x 2 = 4.813, P = 0.028); 23 cases (62.2%) of the treatment group had the cough symptom disappeared, which was significantly better than 14 cases (35.9%) of the control group (x 2 = 5.243, P = 0.022); the differences in the above comparisons between groups were all statistically significant (P < 0.05). The results are shown in Table 13. Table 13 Comparison of the disappearance rates of the main symptoms in the two groups of patients 2.3 Comparison of the disappearance times of the main symptoms in the two groups of patients There were 36 cases of patients with fever disappeared in the treatment group, with an average duration of (2.9 ± 1.67) days, 19 cases of patients with fatigue disappeared, with an average duration of (3.5 ± 1.50) days, and 23 cases of patients with cough disappeared, with an average duration of (3.9 ± 1.98) days; there were 25 cases of patients with fever disappeared in the control group, with an average duration of (3.9 ± 1.29) days, 12 cases of patients with fatigue disappeared, with an average duration of (4.8 ± 1.53) days, and 14 cases of patients with cough disappeared, with an average duration of (5.2 ± 1.76) days. The disappearance times of the main symptoms (fever, fatigue, cough) in the treatment group were all shorter than those in the control group, and the differences in the comparison between groups were all statistically significant (P < 0.05). The results are shown in Table 14. Table 14 Comparison of the disappearance times of the main symptoms in the two groups of patients 2.4 Comparison of the effective rates of the main symptoms in the two groups of patients After 7 days of treatment, among the 51 patients in the treatment group, 44 cases were effective in the treatment of the main symptoms, with an effective rate of 86.3%; among the 51 patients in the control group, 35 cases were effective in the treatment of the main symptoms, with an effective rate of 68.6%, and the difference in the comparison between groups was statistically significant (P = 0.033). 2.5 Comparison of the disappearance rates of other symptoms and signs in the two groups of patients ① Baseline data: There were 51 cases in the treatment group, including 9 cases (17.7%) of muscle pain, 20 cases (39.2%) of expectoration, 13 cases (25.5%) of shortness of breath, 11 cases (21.6%) of chest tightness, 3 cases (5.9%) of dyspnea, 7 cases (13.7%) of nausea, 23 cases (45.1%) of loss of appetite, and 22 cases (43.1%) of pulmonary moist rales; there were 51 cases in the control group, including 11 cases (21.6%) of muscle pain, 19 cases (37.3%) of expectoration, 14 cases (27.5%) of shortness of breath, 19 cases (37.3%) of chest tightness, 7 cases (13.7%) of dyspnea, 5 cases (9.8%) of nausea, 26 cases (51.0%) of loss of appetite, and 23 cases (45.1%) of pulmonary moist rales; there was no significant difference between the groups (P > 0.05). ② After 7 days of treatment, in the treatment group, 11 cases (55.0%) of expectoration, 8 cases (61.5%) of shortness of breath, 6 cases (54.6%) of chest tightness, 8 cases (34.8%) of loss of appetite, and 10 cases (45.5%) of pulmonary moist rales disappeared; in the corresponding control group, 3 cases (15.8%), 2 cases (14.3%), 3 cases (15.8%), 2 cases (7.7%), and 3 cases (13.0%) disappeared respectively, and the differences between the two groups were statistically significant (P < 0.05); in the treatment group, 6 cases (66.7%) of muscle pain, 2 cases (66.7%) of dyspnea, and 4 cases (57.1%) of nausea disappeared; in the corresponding control group, 2 cases (18.2%), 2 cases (28.6%), and 2 cases (40.0%) disappeared respectively, and there was no significant difference between the two groups (P > 0.05). The results are shown in Table 15. Table 15 Comparison of the disappearance rates of other symptoms and signs in the treatment group and the control group 2.6 Analysis of the conversion to severe cases during the treatment process in the two groups of patients There were 51 cases in the treatment group, and 4 cases (7.8%) converted to severe cases during the treatment process; there were 51 cases in the control group, and 11 cases (21.6%) converted to severe cases, and the difference between the groups was statistically significant (P < 0.05). 2.7 Comparison of the improvement rates of pulmonary imaging (CT) in the two groups After 7 days of treatment, in the treatment group of 51 cases, 28 cases (54.9%) showed improvement in pulmonary CT; in the control group of 51 cases, 23 cases (45.1%) showed improvement in pulmonary CT, and there was no significant difference between the groups (P > 0.05). Clinical research results show that after administration of the pharmaceutical composition of the present invention, the symptoms of early and middle-stage patients with the common type are significantly improved, and they are easily cured after treatment. Moreover, the conversion of middle-stage patients to severe cases is significantly reduced, effectively avoiding the conversion to severe and critical conditions. In addition, after critically ill patients take the pharmaceutical composition of the present invention, the blood oxygen saturation is stable, the dyspnea is improved, the absorption of lung inflammation is promoted, and sequelae such as interstitial pneumonia and pulmonary fibrosis are avoided. The results show that the pharmaceutical composition of the present invention can significantly improve the clinical symptoms and signs related to the disease, such as fever, cough, fatigue, shortness of breath, and moist rales in the lungs. At the same time, the proportion of patients in the treatment group converting to severe cases also shows an obvious downward trend, indicating that the pharmaceutical composition of the present invention has good clinical efficacy in helping improve clinical symptoms and relieve the severity of the disease in suspected cases. Experimental Example 6 In vitro cell research 1. Materials and methods 1.1 Cell lines and viruses: African green monkey kidney epithelial cells (Vero E6) and human hepatocellular carcinoma cell line Huh-7 were purchased from ATCC. Culture conditions: Dulbecco's Modified Eagle Medium (DMEM, Gibco, USA) containing 10% fetal bovine serum (FBS). Culture temperature: 37°C. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a clinical isolate from the First Affiliated Hospital of Guangzhou Medical University. 1.2 Test articles: A. The pharmaceutical composition of the present invention (LHQW, Example 4). Preparation and storage of the stock solution of the test article: Dissolve the test article in dimethyl sulfoxide (DMSO) and store at -20°C. B. Remdesivir, provided by Professor Zhang Jiancun of the Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences. Remdesivir was dissolved in DMEM medium. 1.3 Cytotoxicity test: Evaluate the cytotoxic effect of LHQW on Vero E6 cells and Huh-7 cells by the MTT method. Discard the original culture medium of the monolayer Vero E6 cells and Huh-7 cells grown in 96-well plates, wash with PBS, and add test article solutions at different concentrations and incubate for 72 hours. After 72 hours, stain the cells with 0.5 mg / mL MTT solution for 4 hours. Discard the supernatant, and dissolve the formed formazan crystals in 200 μL dimethyl sulfoxide (DMSO). Use a full-wavelength microplate reader (Thermo Fisher, USA) to measure the absorbance at 570 nm. 1.4 Cytopathic effect inhibition assay: Vero E6 cells were inoculated in a 96-well plate. After they grew to a monolayer, a coronavirus strain with a titer of 100 TCID50 was inoculated and cultured at 37 °C for 2 hours. The culture medium was discarded, and LHQW solutions at different concentrations or the positive control remdesivir were added, and incubated for 72 hours. After 72 hours, 100% cytopathic effect was shown by the infected Vero E6 cells under the microscope. The percentage of cytopathic effect in the cells treated with LHQW was recorded. Calculate the half-maximal inhibitory concentration (IC 50 ). 1.5 Plaque reduction assay: Vero E6 cells were cultured to a monolayer in a 6-well plate. The supernatant was discarded, rinsed with PBS, and 50 PFU of SARS-CoV-2 virus was added to the plate and incubated for 2 hours. The supernatant was discarded, and basal medium containing 1.2% agarose (Invitrogen, USA) per milliliter and LHQW at different concentrations or the positive control remdesivir were added. After incubation at 37 °C for 48 hours, it was fixed with 4% formalin for 20 minutes and stained with 1% crystal violet for 3 minutes. Calculate the plaque inhibition rate and calculate the half-maximal inhibitory concentration (IC 50 ) of the drug against the virus. 1.6 RT-qPCR method: The Huh-7 monolayer cells inoculated in a 12-well plate were rinsed with PBS and infected with the coronavirus at a multiplicity of infection MOI = 1 at 37 °C for 2 hours. The supernatant was discarded, and the test article was diluted to the required concentration with medium containing 2% FBS and added to the 12-well plate, and continuously incubated for 48 hours. The collected cells were used for RNA isolation and qPCR detection. The primer and probe sequences for analysis are shown in Table 16. Using GAPDH as an internal reference factor, the relative mRNA expression was calculated by the 2-ΔΔCt method. Table16 Primers for qRT-PCR used in this study 1.7 Electron microscopy analysis: The cells were fixed, dehydrated and embedded. The embedded wax blocks were cut into ultra-thin sections of 70 nm. Stained with uranyl acetate and lead citrate, and then read under a JEM-1400PLUS transmission electron microscope. 2. Statistical analysis Statistical analysis was performed using GraphPad Prism 7.0 software. One-way analysis of variance (ANOVA) was used to compare the differences in the mRNA expression levels of pro-inflammatory cytokines in each group. The test statistical significance level was set at p < 0.05. 3. Results 3.1 In vitro antiviral activity of LHQW against SARS-CoV-2 The cell viability of Vero E6 cells treated with LHQW or remdesivir was determined by the MTT assay. At a concentration of 600 μg / mL, LHQW had obvious cytotoxicity to Vero E6 cells (the results are shown in Figure 4A). The positive control remdesivir had no cytotoxicity to cells at a concentration of 50 μM (the results are shown in Figure 4B). As shown in Figure 5A, the inhibitory effect of LHQW on SARS-CoV-2 virus was detected by the cytopathic effect inhibition test and the plaque reduction assay, and the IC 50 value was 411.2 μg / mL (see Figures 5A and 5C). The IC 50 value of remdesivir for SARS-CoV-2 virus was 0.651 μM. Forty-eight hours after virus infection of Vero E6 cells, virus particles were found in the cytoplasm, intracellular vesicles, endoplasmic reticulum and cell membrane, and the typical coronavirus morphology was observed under the electron microscope (see Figures 6B and 6F). After treatment with LHQW (600 μg), the virus expression level decreased (see Figures 6C and 6G). More significantly, the cells treated with LHQW changed the virus morphology: there were many oval virus particles on the cell surface (see Figure 6H), which was different from the spherical and pointed virus particles in the virus-infected cells (see Figures 6B and 6F). 3.2 Inhibitory effect of LHQW on the expression of cytokines and chemokines induced by SARS-CoV-2 To determine the role of LHQW in inhibiting the expression of cytokines and chemokines induced by SAR2-CoV-2, the mRNA expression levels of TNF-α, IL-6, CCL-2 / MCP-1 and CXCL-10 / IP-10 in cells were measured after treatment with LHQW. The results showed that the expression of cytokines and chemokines increased 48 hours after virus infection, and LHQW had an obvious inhibitory effect on these cytokines and chemokines, and this inhibitory effect was concentration-dependent. The results are shown in Figure 7. Conclusion The above research results show that the pharmaceutical composition LHQW of the present invention can play an anti-SARS-CoV-2 activity role by inhibiting virus replication and reducing the release of cytokines from host cells.
Claims
1. Use of a pharmaceutical composition in the preparation of a medicament for preventing and treating pneumonia caused by novel coronavirus infection, wherein the pharmaceutical composition is made from the following raw materials in parts by weight:
2. The use according to claim 1, wherein the pharmaceutical composition is made from the following raw materials in parts by weight:
3. The use according to claim 1, wherein the pharmaceutical composition is made from the following raw materials in parts by weight:
4. The use according to claim 1, wherein the pharmaceutical composition is made from the following raw materials in parts by weight:
5. The use according to claim 1, wherein the pharmaceutical composition is made from the following raw materials in parts by weight:
6. The use according to any one of claims 1-5, wherein the active ingredient of the pharmaceutical composition is prepared by the following steps: (1) Weigh traditional Chinese medicinal materials according to the weight ratio of raw materials, and perform cleaning and selection; (2) Cut Pogostemon cablin into sections, add 5-8 times the amount of water to extract volatile oil, extract for 4 hours, collect the volatile oil and set aside; after filtering the extract, discard the residue and reserve the filtrate; (3) Forsythia suspensa, Ephedra sinica preparata, Houttuynia cordata, Rheum palmatum, extract with 6-10 times the amount of 50-90% ethanol for 2 times, each time for 1-3 hours, combine and filter the extracts, recover ethanol, and reserve the ethanol extract; (4) Flos Lonicerae, Gypsum fibrosum, Radix Isatidis, Dryopteris crassirhizoma, Glycyrrhiza uralensis, Rhodiola rosea, add 7-11 times the amount of water and boil until boiling, add Semen Armeniacae Amarum stir-fried, decoct for 2 times, each time for 0.5-2.5 hours, combine and filter the extracts, combine the obtained filtrate with the filtrate after extracting volatile oil from Pogostemon cablin in step (2), concentrate to a clear paste with a relative density of 1.10-1.15 measured at 60°C, add ethanol, adjust the ethanol concentration to 70%, refrigerate and stand, filter, recover ethanol until there is no alcohol smell, and obtain a clear paste for standby; (5) Combine the clear paste obtained in step (4) with the ethanol extract obtained in step (3), concentrate to a clear paste with a relative density of 1.15-1.20 measured at 60°C, dry to obtain dry paste powder for standby; (6) Mix the dry paste powder obtained in step (5), the volatile oil obtained in step (2) and menthol to prepare the active ingredient of the pharmaceutical composition.
7. The use according to any one of claims 1-5, wherein the medicament is in the form of a capsule, tablet, powder, granule, oral liquid, pill, tincture, syrup, suppository, gel, spray or injection.
8. The use according to claim 7, wherein the capsule is prepared by a method comprising the following steps: (1) Weigh traditional Chinese medicinal materials according to the weight ratio of raw materials, and perform cleaning and selection; (2) Cut Pogostemon cablin into sections, add 5-8 times the amount of water to extract volatile oil, extract for 4 hours, collect the volatile oil and set aside; after filtering the extract, discard the residue and reserve the filtrate; (3) Forsythia suspensa, Ephedra sinica preparata, Houttuynia cordata, Rheum palmatum, extract with 6-10 times the amount of 50-90% ethanol for 2 times, each time for 1-3 hours, combine and filter the extracts, recover ethanol, and reserve the filtrate; (4) Flos Lonicerae, Gypsum Fibrosum, Radix Isatidis, Dryopteris Crassirhizoma, Glycyrrhiza Uralensis Fisch., Rhodiola Rosea, add 7 - 11 times the amount of water and decoct until boiling, add stir-fried Semen Armeniacae Amarum, decoct twice, each time for 0.5 - 2.5 hours, combine and filter the extraction solutions, combine the obtained filtrate with the filtrate after essential oil extraction of Pogostemon Cablin in step (2), concentrate to a clear paste with a relative density of 1.10 - 1.15 measured at 60 °C, add ethanol, adjust the ethanol concentration to 70%, refrigerate and stand, filter, recover ethanol until there is no ethanol smell, obtain a clear paste for standby; (5) Combine the clear paste obtained in step (4) with the ethanol extract obtained in step (3), concentrate to a clear paste with a relative density of 1.15 - 1.20 measured at 60 °C, dry to obtain dry paste powder for standby; (6) Add appropriate pharmaceutically acceptable excipients to the dry paste powder obtained in step (5) to prepare granules; (7) Dissolve Menthol and the volatile oil obtained in step (2) in ethanol, spray it into the granules obtained in step (6), seal, mix evenly, fill into capsules to obtain the product.
9. The application according to claim 7, wherein the granule is prepared by a method comprising the following steps: (1) Weigh traditional Chinese medicinal materials according to the weight ratio of the raw materials, perform cleaning and selection, and break them as appropriate; (2) Break Pogostemon Cablin, add 5 - 8 times the amount of water to extract volatile oil, the extraction time is 4 hours, collect the volatile oil for standby; after filtering the extraction solution, discard the residue and reserve the filtrate; (3) Forsythia Suspensa, Ephedra Praeparata, Houttuynia Cordata Thunb., Rheum Palmatum L., extract with 6 - 10 times the amount of 50 - 90% ethanol twice, each time for 1 - 3 hours, combine and filter the extraction solutions, recover ethanol, and reserve the filtrate; (4) Flos Lonicerae, Gypsum Fibrosum, Radix Isatidis, Dryopteris Crassirhizoma, Glycyrrhiza Uralensis Fisch., Rhodiola Rosea, add 7 - 11 times the amount of water and decoct until boiling, add stir-fried Semen Armeniacae Amarum, decoct twice, each time for 0.5 - 2.5 hours, combine and filter the extraction solutions, combine the obtained filtrate with the filtrate after essential oil extraction of Pogostemon Cablin in step (2), concentrate to a clear paste with a relative density of 1.10 - 1.15 measured at 60 °C, add ethanol, adjust the ethanol concentration to 70%, refrigerate and stand, filter, recover ethanol until there is no ethanol smell, obtain a clear paste for standby; (5) Combine the clear paste obtained in step (4) with the ethanol extract obtained in step (3), concentrate to a clear paste with a relative density of 1.15 - 1.20 measured at 60 °C, dry to obtain dry paste powder for standby; (6) Add appropriate pharmaceutically acceptable excipients to the dry paste powder obtained in step (5) to prepare granules; (7) Dissolve Menthol and the volatile oil obtained in step (2) in ethanol, spray it into the granules obtained in step (6), seal, mix evenly, bag it to obtain the product.
10. The application according to claim 9, wherein the granule is prepared by a method comprising the following steps: (1) Weigh traditional Chinese medicinal materials according to the weight ratio of the raw materials, perform cleaning and selection, and break them as appropriate; (2) Break Pogostemon Cablin, add 6 times the amount of water to extract volatile oil, the extraction time is 4 hours, collect the volatile oil, the oil yield is 0.33 ± 0.05%, for standby; after filtering the extraction solution, discard the residue and reserve the filtrate; (3) Forsythia suspensa, Ephedra praeparata, Houttuynia cordata, and Rheum palmatum are extracted twice with 8 times the amount of 70% ethanol, for 2 hours for the first time and 1.5 hours for the second time. The extraction solutions are combined and filtered, the ethanol is recovered, and the filtrate is reserved for use. (4) Flos Lonicerae, Gypsum fibrosum, Radix Isatidis, Dryopteris crassirhizoma, Glycyrrhiza uralensis, and Rhodiola rosea are decocted with 9 times the amount of water until boiling, and stir-fried Armeniaca vulgaris var. ansu and are added and decocted twice, for 1.5 hours for the first time and 1 hour for the second time. The extraction solutions are combined and filtered, and the obtained filtrate is combined with the water extraction solution after essential oil extraction from Pogostemon cablin in step (2), concentrated into a clear extract with a relative density of 1.10 - 1.15 measured at 60°C, 95% ethanol is added, the alcohol concentration is adjusted to 70%, refrigerated and left standing, filtered, and the ethanol is recovered until there is no alcohol smell to obtain a clear extract. (5) The clear extract obtained in step (4) is combined with the alcohol extract obtained in step (3), concentrated to a thick extract with a relative density of 1.15 - 1.20 measured at 60°C, and reserved for use. (6) Appropriate pharmaceutically acceptable excipients are added to the thick extract obtained in step (5) to prepare granules, sized, and reserved for use. (7) The fine powder is screened out from the granules obtained in step (6), Menthol and the volatile oil obtained in step (2) are dissolved in ethanol, sprayed into the fine powder, mixed evenly, then mixed evenly with the granules obtained in step (6), sealed for half an hour, bagged, and ready.
11. The use according to any one of claims 1 - 5, wherein the drug is used to improve shortness of breath and / or dyspnea.
12. The use according to any one of claims 1 - 5, wherein the drug is used to improve fever, cough, and fatigue.
13. The use according to any one of claims 1 - 5, wherein the drug is used to improve chest tightness.
14. The use according to any one of claims 1 - 5, wherein the drug is used to improve pulmonary moist rales.
15. The use according to any one of claims 1 - 5, wherein the drug is used to inhibit the elevation of cytokines and chemokines.
16. The use according to claim 15, wherein the cytokines and chemokines are selected from TNF-α, IL-6, CCL-2 / MCP-1, and CXCL-10 / IP-10.
